Skip to main navigation
Go to  Indivior Pharmaceuticals, Inc. corporate website
  • Overview
  • News & Events
    • Results, Reports & Presentations
    • News Releases
    • Events
  • Stock
    • Stock Quote & Chart
    • Historical Price Lookup
    • Analyst Coverage
  • Shareholder Info
    • Redomiciliation
    • London Delisting
    • Managing Your Shares
    • Shareholder Meetings
    • Investor FAQs
  • Governance
    • Governance Overview
    • Committees
    • Tax Strategy
  • Financials
    • SEC Filings
    • RNS Filings
  • Resources
    • Contact Us
    • Alerts Service
News & Events
  • Results, Reports & Presentations
  • News Releases
  • Events

News Releases

  • 2026
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
December 20, 2023
Indivior Settles Patent Dispute with Teva Subsidiary Actavis
December 5, 2023
Indivior Prevails in Striking Representative Claims from UK Shareholder Action
November 9, 2023
Indivior Announces Q3 2023 Financial Results
October 23, 2023
Indivior Reaches Agreement with Direct Purchasers to Resolve Antitrust Multi-District Litigation; Provides Preliminary Q3 and YTD 2023 Results
October 11, 2023
Indivior Enters an Exclusive Licensing Agreement with Alar Pharmaceuticals
August 21, 2023
Indivior Reaches Agreement with End Payor Class to Resolve Their Antitrust Multi-District Litigation Claims
July 27, 2023
Indivior Announces H1 and Q2 2023 Financial Results
June 14, 2023
Indivior Announces Four Abstracts Accepted for Presentation at the 85th Annual Scientific Meeting of the College on Problems of Drug Dependence
June 12, 2023
Indivior to Commence Trading on Nasdaq
June 2, 2023
Indivior Reaches Agreement with States’ Attorneys General and District of Columbia to Resolve Antitrust Multi-District Litigation Claims
  • Current page 1
  • Page 2
  • Next page ›
  • Last page »
Displaying 1 - 10 of 17

Investor Contact

person Jason Thompson
Work Vice President, Investor Relations
drafts InvestorRelations@indivior.com

Subscribe to our Email Alerts

Indivior Pharmaceuticals, Inc. Logo
Indivior Pharmaceuticals, Inc. Logo
© 2026 Indivior Pharmaceuticals, Inc.
This site is intended for US audiences
INDIVIOR is a registered trademark of Indivior UK Limited
Explore
  • Our Company
  • Our Science
  • Our Products
  • Our Impact
Useful Links
  • Terms of Use
  • Privacy Policy
  • Accessibility
  • Cookie Policy
  • Product Query or Adverse Event
Get in touch
  • Contact Us
  • LinkedIn
  • X
  • Our Social Media Community Guidelines
Search Investors